Figure 1
Figure 1. Growth of MOLM-14 and MV4–11 AML cells is inhibited by GO-201. (A) MOLM-14 (top panels) and MV4-11 (bottom panels) were incubated with a control IgG or anti–MUC1-N (MAb DF3) and analyzed by flow cytometry. The percentage of MUC1-positive cells is indicated in the panels. (B) Lysates from MOLM-14 and MV4-11 cells were subjected to immunoblotting with the indicated antibodies. (C) Amino acid sequences of GO-201 and CP-1. MOLM-14 cells were left untreated (♦), and treated with 5μM GO-201 (■) or 5μM CP-1 (▵) each day for the indicated days. Viable cell number as determined by trypan blue exclusion is expressed as the mean ± SD of 3 determinations. (D) MV4-11 cells were left untreated (♦), and treated with 5μM GO-201 (■) or 5μM CP-1 (▵) each day for the indicated days. Viable cell number was determined by trypan blue exclusion.

Growth of MOLM-14 and MV4–11 AML cells is inhibited by GO-201. (A) MOLM-14 (top panels) and MV4-11 (bottom panels) were incubated with a control IgG or anti–MUC1-N (MAb DF3) and analyzed by flow cytometry. The percentage of MUC1-positive cells is indicated in the panels. (B) Lysates from MOLM-14 and MV4-11 cells were subjected to immunoblotting with the indicated antibodies. (C) Amino acid sequences of GO-201 and CP-1. MOLM-14 cells were left untreated (♦), and treated with 5μM GO-201 (■) or 5μM CP-1 (▵) each day for the indicated days. Viable cell number as determined by trypan blue exclusion is expressed as the mean ± SD of 3 determinations. (D) MV4-11 cells were left untreated (♦), and treated with 5μM GO-201 (■) or 5μM CP-1 (▵) each day for the indicated days. Viable cell number was determined by trypan blue exclusion.

Close Modal

or Create an Account

Close Modal
Close Modal